Ikena Oncology, Inc.
NASDAQ Global MarketTotal Valuation
Ikena Oncology, Inc. carries a market capitalization of 718.82M, placing it among publicly traded companies globally. Its enterprise value stands at -84.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 718.82M |
| Enterprise Value | -84.58M |
Share Statistics
Ikena Oncology, Inc. currently has 48.26M shares outstanding.
| Shares Outstanding | 48.26M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.02 |
| P/TBV Ratio | 0.05 |
| P/FCF Ratio | -0.18 |
| P/OCF Ratio | -0.18 |
Financial Position
Ikena Oncology, Inc. maintains a current ratio of 13.52, meaning it holds 13.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 13.52 |
| Quick Ratio | 13.06 |
| Debt / Equity | 4.90 |
| Debt / EBITDA | -0.14 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -21.68 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 106,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Ikena Oncology, Inc.'s stock has declined approximately -22.7027% over the past 52 weeks. The 50-day moving average sits at 15.75, while the 200-day moving average is 17.08.
| Beta (5Y) | N/A |
| 52-Week Price Change | -22.7027% |
| 50-Day Moving Average | 15.75 |
| 200-Day Moving Average | 17.08 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -41.22M, while operating income came in at -41.57M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -41.57M |
| Pretax Income | -30.64M |
| Net Income | -30.74M |
| EBITDA | -41.22M |
| EBIT | -41.57M |
| Earnings Per Share (EPS) | -7.64 |
Balance Sheet
Ikena Oncology, Inc. holds 95.64M in cash and equivalents against 5.68M in total debt, resulting in a net debt position of -58.29M. Total book value stands at -342.96M, with working capital of 91.69M providing operational flexibility.
| Cash & Cash Equivalents | 95.64M |
| Total Debt | 5.68M |
| Net Debt | -58.29M |
| Equity (Book Value) | -342.96M |
| Book Value Per Share | -85.28 |
| Working Capital | 91.69M |
Cash Flow
Ikena Oncology, Inc. produced -29.18M in operating cash flow over the past twelve months.
| Operating Cash Flow | -29.18M |
| Capital Expenditures | N/A |
| Free Cash Flow | -29.18M |
| FCF Per Share | -7.26 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -541.53 |
Stock Splits
Ikena Oncology, Inc.'s most recent stock split took place on July 28, 2025 with a 12:1 split ratio.
| Last Split Date | 7/28/2025 |
| Split Ratio | 12:1 |
Scores
Ikena Oncology, Inc. posts an Altman Z-Score of -3.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.71 |